Skip to main content

Recce Pharmaceuticals Announces RECCE® Trademark Registered in Vietnam, Strengthening Global IP Portfolio

Written by Customer Service on . Posted in Public Companies.

SYDNEY, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to announce it has been issued a trademark registration for RECCE® from the Intellectual Property Office of Vietnam, strengthening the Company’s global intellectual property (IP) portfolio.

The International Trademark Registration No. 1289603 has been formally assigned to the International Bureau (World Intellectual Property Organization), classified under Class 5 for antibiotics, antibiotics for human use, and pharmaceutical preparations, namely mixed antibiotic preparations.

“We are thrilled to receive this newly awarded trademark in Vietnam, further strengthening Recce’s intellectual property portfolio in the Asia-Pacific region,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals. “This trademark is a welcomed advance and will support our ongoing fight against the global health threat of antibiotic-resistant superbugs.”

In 2020, Vietnam’s pharmaceutical market was valued at approximately $10 billion, doubling in value since 2015, with the projected value reaching $16.1 billion in 2026.1 Antibiotic resistance in Vietnam is amongst the highest in the world.2 Last resort antibiotics such as carbapenems or colistin are used frequently in intensive care units of large hospitals in Vietnam, which drives bacterial pathogens to develop resistance, eventually rendering them immune to common treatments.3

This trademark builds upon RECCE® registrations in the largest pharmaceutical markets in the world, such as the United States, Israel, China, Australia, Japan, Hong Kong, and Europe.

About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a new class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.

Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.

Corporate Contact
James Graham
Recce Pharmaceuticals Ltd
+61 (02) 9256 2571
James.graham@recce.com.au

Media & Investor Relations (AU)
Andrew Geddes
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au

Media (USA)
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Relations (USA & EU)
Guillame van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com

1 Vietnam’s growing Pharmaceutical Industry
2 Action Intervention to Tackle Antibiotic Resistance: Experiences From Northern Vietnam
3 University of Oxford: Tackling the super bug threat in Vietnam

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.